358 were allocated to placebo and 360 to Interferon B-1b. Interferon B-1a administered subcutaneously 3 times a week significantly reduced the relapse rate, and prolonged the time to first relapse in patients with Multiple Sclerosis. Interferon B-1a also significantly delayed the progression of disability. Melhus H, Michaelsson K, Kindmark A, et al. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture.
Retinoic acid is known to inhibit bone formation and to increase bone resorption.
Hu FB, Stampfer MJ, Manson JE, et al. These results were based on a prospective cohort study which included 86,016 women aged 34 to 59 years without previously diagnosed coronary heart disease, stroke or cancer at baseline in 1980.